. Andy Mulvaney has 15 years’ biotech experience in operational, business development and alliance management roles, most recently as Vice President, Business Development at Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM).  In 2003 he co-founded VASTox Ltd., now Summit Therapeutics plc, with Professor Stephen Davies and Professor Dame Kay Davies to develop utrophin modulation as a disease-modifying strategy for Duchenne Muscular Dystrophy.  Andy initially served as Chief Operating Officer and in October 2004 was instrumental in the successful IPO of VASTox on the AIM segment of the London Stock Exchange.  From 2006, Andy focussed on strategic partnering and completed a number of global and regional licensing transactions, acquisitions and divestments, with deal values exceeding $1.3Bn.  Andy is a member of the Pharmaceutical Licensing Group. Andy was a postdoctoral fellow in the Dyson Perrins Laboratory, University of Oxford, working with Professor Stephen Davies, establishing the group’s activities in utrophin modulation, chemical genetics and combinatorial chemistry. Andy obtained an honours degree in Chemistry with Business Studies from the University of Wales. Staying in Wales, Andy subsequently gained a Ph.D. from Cardiff University investigating homogeneous catalysis using organometallic complexes, having been awarded a prestigious fully funded scholarship by open competition from ICI. . Andy Mulvaney has 15 years’ biotech experience in operational, business development and alliance management roles, most recently as Vice President, Business Development at Summit Therapeutics plc (NASDAQ: SMMT; AIM: SUMM).  In 2003 he co-founded VASTox Ltd., now Summit Therapeutics plc, with Professor Stephen Davies and Professor Dame Kay Davies to develop utrophin modulation as a disease-modifying strategy for Duchenne Muscular Dystrophy.  Andy initially served as Chief Operating Officer and in October 2004 was instrumental in the successful IPO of VASTox on the AIM segment of the London Stock Exchange.  From 2006, Andy focussed on strategic partnering and completed a number of global and regional licensing transactions, acquisitions and divestments, with deal values exceeding $1.3Bn.  Andy is a member of the Pharmaceutical Licensing Group. Andy was a postdoctoral fellow in the Dyson Perrins Laboratory, University of Oxford, working with Professor Stephen Davies, establishing the group’s activities in utrophin modulation, chemical genetics and combinatorial chemistry. Andy obtained an honours degree in Chemistry with Business Studies from the University of Wales. Staying in Wales, Andy subsequently gained a Ph.D. from Cardiff University investigating homogeneous catalysis using organometallic complexes, having been awarded a prestigious fully funded scholarship by open competition from ICI.

fermentation